2/12
07:30 am
flgt
Fulgent to Announce Fourth Quarter and Full Year 2025 Financial Results on Friday, February 27, 2026
Low
Report
Fulgent to Announce Fourth Quarter and Full Year 2025 Financial Results on Friday, February 27, 2026
2/11
07:23 am
flgt
Fulgent Genetics (NASDAQ:FLGT) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Low
Report
Fulgent Genetics (NASDAQ:FLGT) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
1/27
04:05 am
flgt
Fulgent Genetics: The Price Has Caught Up To Value, But I Still Like The Stock [Seeking Alpha]
Low
Report
Fulgent Genetics: The Price Has Caught Up To Value, But I Still Like The Stock [Seeking Alpha]
1/13
05:44 am
flgt
Fulgent Genetics (NASDAQ:FLGT) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Low
Report
Fulgent Genetics (NASDAQ:FLGT) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
1/12
11:02 am
flgt
Fulgent Genetics to Acquire Bako Diagnostics Assets and StrataDx for $55.5 Million [Los Angeles Times (CA)]
Low
Report
Fulgent Genetics to Acquire Bako Diagnostics Assets and StrataDx for $55.5 Million [Los Angeles Times (CA)]
12/23
02:16 am
flgt
Fulgent Genetics to buy Bako Diagnostics assets and StrataDx [Yahoo! Finance]
Low
Report
Fulgent Genetics to buy Bako Diagnostics assets and StrataDx [Yahoo! Finance]
12/22
04:29 pm
flgt
Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx [Yahoo! Finance]
Low
Report
Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx [Yahoo! Finance]
12/22
04:10 pm
flgt
Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx
Low
Report
Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx
12/2
08:09 am
flgt
Fulgent Genetics: From Genetic Code To Cancer Cure - Why I Assign A Hold Rating [Seeking Alpha]
Low
Report
Fulgent Genetics: From Genetic Code To Cancer Cure - Why I Assign A Hold Rating [Seeking Alpha]
11/14
07:22 am
flgt
Fulgent Genetics (NASDAQ:FLGT) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc..
Low
Report
Fulgent Genetics (NASDAQ:FLGT) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc..